Market Summary
USD199.27+0.90
Market Closed0.45%
SGEN Stock Price
SGEN RSI Chart
SGEN Valuation
SGEN Price/Sales (Trailing)
SGEN Profitability
SGEN Fundamentals
SGEN Revenue
SGEN Earnings
Price Action
52 Week Range
105.43202.86
(Low)(High)
Last 7 days
-0.6%
Last 30 days
27.3%
Last 90 days
56.9%
Trailing 12 Months
43.6%
SGEN Financial Health
SGEN Investor Care
Peers (Alternatives to Seagen)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 124.2B | 26.3B | -2.34% | 1.62% | 18.96 | 4.72 | 1.32% | 11.18% |
GILD | 98.0B | 27.3B | -7.18% | 37.83% | 21.33 | 3.59 | -0.09% | -26.23% |
MRNA | 57.1B | 19.3B | -7.28% | -16.95% | 6.83 | 2.97 | 4.29% | -31.47% |
BIIB | 38.1B | 10.2B | -3.01% | 25.82% | 12.5 | 3.74 | -7.36% | 95.80% |
| MID-CAP | ||||||||
NBIX | 9.2B | 1.5B | -6.54% | 2.94% | 59.61 | 6.19 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -20.63% | -31.77% | -9.51 | 28.59 | 122.90% | -12.19% |
BEAM | 2.2B | 60.9M | -22.54% | -46.32% | -7.52 | 35.66 | 17.51% | 22.00% |
BBIO | 1.9B | 107.9M | 7.80% | 19.42% | -3.99 | 17.93 | 54.84% | 17.36% |
| SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -12.49% | -50.70% | -4.44 | 10.58 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -19.12% | 19.58% | -7.01 | 156.87 | 131.81% | -45.39% |
FATE | 507.9M | 96.3M | -13.43% | -85.87% | -1.8 | 5.27 | 72.44% | -32.79% |
NVAX | 499.9M | 2.0B | -38.13% | -92.75% | -0.76 | 0.25 | 72.89% | 62.27% |
SGMO | 278.5M | 111.3M | -41.20% | -71.01% | -1.45 | 2.5 | 0.54% | -7.86% |
VXRT | 98.0M | 107.0K | -22.42% | -85.54% | -0.91 | 915.57 | -88.00% | -52.91% |
IBIO | 26.6M | - | 29.52% | -80.89% | -0.33 | 3.21 | 0.51% | -185.61% |
Financials for Seagen
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 5.3% | 1,962,412,000 | 1,864,113,000 | 1,777,873,000 | 1,668,849,000 | 1,574,371,000 |
| S&GA Expenses | 0.6% | 820,963,000 | 815,799,000 | 785,702,000 | 730,573,000 | 716,190,000 |
| R&D Expenses | 4.1% | 1,344,361,000 | 1,290,812,000 | 1,365,299,000 | 1,295,906,000 | 1,228,672,000 |
| Costs and Expenses | 3.2% | 2,575,382,000 | 2,495,149,000 | 2,514,067,000 | 2,361,535,000 | 2,256,427,000 |
| EBITDA | 5.6% | -555,588,000 | -588,369,000 | -693,551,000 | -644,806,000 | - |
| EBITDA Margin | 10.3% | -0.28 | -0.32 | -0.39 | -0.39 | - |
| Earnings Before Taxes | 5.2% | -602,315,000 | -635,461,000 | -739,669,000 | -689,525,000 | -675,705,000 |
| EBT Margin | 10.0% | -0.31 | -0.34 | -0.42 | -0.41 | - |
| Net Income | 4.2% | -610,308,000 | -636,765,000 | -739,796,000 | -689,545,000 | -674,471,000 |
| Net Income Margin | 9.0% | -0.31 | -0.34 | -0.42 | -0.41 | - |
| Free Cahsflow | 26.2% | -531,091,000 | -719,364,000 | -651,907,000 | -652,705,000 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 1.5% | 3,675 | 3,619 | 3,630 | 3,617 | 3,720 |
| Current Assets | 1.6% | 2,803 | 2,760 | 2,779 | 2,771 | 2,869 |
| Cash Equivalents | -11.8% | 320 | 363 | 365 | 261 | 425 |
| Inventory | 17.1% | 427 | 365 | 319 | 276 | 201 |
| Net PPE | 7.8% | 248 | 230 | 219 | 214 | 210 |
| Goodwill | 0% | 275 | 275 | 275 | 275 | 275 |
| Current Liabilities | 12.7% | 818 | 726 | 609 | 531 | 569 |
| Shareholder's Equity | -0.6% | 2,804 | 2,822 | 2,933 | 2,998 | 3,065 |
| Retained Earnings | -7.4% | -2,154 | -2,006 | -1,815 | -1,680 | -1,544 |
| Additional Paid-In Capital | 2.7% | 4,954 | 4,825 | 4,747 | 4,678 | 4,608 |
| Accumulated Depreciation | - | 212 | - | - | - | - |
| Shares Outstanding | 0.7% | 187 | 185 | 184 | 184 | 183 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 31.0% | -453 | -657 | -589 | -590 | -499 |
| Share Based Compensation | 5.8% | 221 | 209 | 195 | 179 | 173 |
| Cashflow From Investing | -14.1% | 228 | 266 | 469 | 394 | 289 |
| Cashflow From Financing | 52.2% | 125 | 82.00 | 86.00 | 85.00 | 78.00 |
Risks for SGEN
What is the probability of a big loss on SGEN?
72.3%
Probability that Seagen stock will be more than 20% underwater in next one year
55.4%
Probability that Seagen stock will be more than 30% underwater in next one year.
0%
Probability that Seagen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SGEN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Seagen was unfortunately bought at previous high price.
Drawdowns
Returns for SGEN
Cumulative Returns on SGEN
18.6%
10-Year Cumulative Returns
28.4%
7-Year Cumulative Returns
31.4%
5-Year Cumulative Returns
26.2%
3-Year Cumulative Returns
What are the long-term rolling returns for SGEN?
FIve years rolling returns for Seagen.
Annualized Returns
Which funds bought or sold SGEN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -2.97 | -1,651,330 | 16,957,700 | 0.02% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | -1,551 | 16,449 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 37.31 | 36,000 | 162,000 | -% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | unchanged | - | -22,598 | 353,402 | 0.02% |
2023-02-28 | Voya Investment Management LLC | added | 19.01 | 9,900,110 | 93,952,100 | 0.13% |
2023-02-27 | Parallax Volatility Advisers, L.P. | new | - | 435,006 | 435,006 | -% |
2023-02-24 | BBJS FINANCIAL ADVISORS, LLC | new | - | 12,851 | 12,851 | 0.01% |
2023-02-24 | National Pension Service | added | 9.34 | 906,189 | 26,488,400 | 0.05% |
2023-02-24 | Garde Capital, Inc. | unchanged | - | -12,000 | 186,000 | 0.02% |
2023-02-24 | NATIXIS | added | 396 | 2,685,390 | 3,419,390 | 0.02% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Seagen News
Schedule 13G FIlings of Seagen
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Mar 13, 2023 | baker bros. advisors lp | 25.1% | 46,985,656 | SC 13D/A | |
| Feb 13, 2023 | capital international investors | 9.7% | 18,058,081 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 6.97% | 12,945,078 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 5.32% | 9,881,292 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.4% | 11,861,464 | SC 13G/A | |
| Mar 10, 2022 | baker bros. advisors lp | 25.6% | 46,975,613 | SC 13D/A | |
| Feb 11, 2022 | capital international investors | 7.0% | 12,778,429 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 6.36% | 11,629,729 | SC 13G | |
| Feb 01, 2022 | blackrock inc. | 7.3% | 13,341,753 | SC 13G/A | |
| May 18, 2021 | baker bros. advisors lp | 26.1% | 47,370,508 | SC 13D/A |
SGEN Fair Value
Seagen fair value in different scenarios
The table shows the Fair Value estimates for Seagen for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 6.67 -96.65% | 10.88 -94.54% | 16.92 -91.51% | 23.73 -88.09% | 31.02 -84.43% |
| Current Inflation | 6.07 -96.95% | 9.73 -95.12% | 14.82 -92.56% | 20.52 -89.70% | 26.64 -86.63% |
| Very High Inflation | 5.34 -97.32% | 8.34 -95.81% | 12.36 -93.80% | 16.81 -91.56% | 21.60 -89.16% |
Historical Seagen Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Seagen
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 17, 2023 | 4 | Insider Trading | |
| Mar 17, 2023 | 4 | Insider Trading | |
| Mar 17, 2023 | 4 | Insider Trading | |
| Mar 16, 2023 | 4 | Insider Trading | |
| Mar 13, 2023 | DEFA14A | DEFA14A | |
| Mar 13, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Mar 13, 2023 | DEFA14A | DEFA14A | |
| Mar 13, 2023 | DEFA14A | DEFA14A | |
| Mar 13, 2023 | DEFA14A | DEFA14A | |
| Mar 13, 2023 | 8-K | Current Report |
Latest Insider Trading transactions for SGEN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-16 | LIU JEAN I | acquired | 195,750 | 39.15 | 5,000 | chief legal officer |
2023-03-16 | LIU JEAN I | sold | -999,500 | 199 | -5,000 | chief legal officer |
2023-03-15 | DANSEY ROGER D | sold | -1,998,120 | 199 | -10,000 | president, r&d & cmo |
2023-03-15 | WELCH DANIEL G | sold | -249,262 | 200 | -1,246 | - |
2023-03-15 | WELCH DANIEL G | acquired | 79,076 | 38.82 | 2,037 | - |
2023-03-15 | WELCH DANIEL G | sold | -471,518 | 200 | -2,357 | - |
2023-03-15 | DANSEY ROGER D | acquired | 726,400 | 72.64 | 10,000 | president, r&d & cmo |
2023-03-14 | WELCH DANIEL G | sold | -57,600 | 200 | -288 | - |
2023-03-14 | WELCH DANIEL G | sold | -108,800 | 200 | -544 | - |
2023-03-14 | WELCH DANIEL G | acquired | 18,245 | 38.82 | 470 | - |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
SGEN Income Statement
2022-12-31Consolidated Statements of Comprehensive (Loss) Income - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues: | |||
| Revenue | $ 1,962,412 | $ 1,574,371 | $ 2,175,536 |
| Costs and expenses: | |||
| Cost of sales | 410,058 | 311,565 | 217,720 |
| Research and development | 1,344,361 | 1,228,672 | 827,129 |
| Selling, general and administrative | 820,963 | 716,190 | 533,835 |
| Total costs and expenses | 2,575,382 | 2,256,427 | 1,578,684 |
| (Loss) income from operations | (612,970) | (682,056) | 596,852 |
| Investment and other income, net | 10,655 | 6,351 | 18,849 |
| (Loss) income before income taxes | (602,315) | (675,705) | 615,701 |
| Provision (benefit) for income taxes | 7,993 | (1,234) | 2,031 |
| Net (loss) income | $ (610,308) | $ (674,471) | $ 613,670 |
| Net (loss) income per share - basic (in dollars per share) | $ (3.30) | $ (3.70) | $ 3.51 |
| Net (loss) income per share - diluted (in dollars per share) | $ (3.30) | $ (3.70) | $ 3.37 |
| Shares used in computation of per share amounts - basic (in shares) | 184,676 | 182,048 | 174,834 |
| Shares used in computation of per share amounts - diluted (in shares) | 184,676 | 182,048 | 182,287 |
| Comprehensive (loss) income: | |||
| Net (loss) income | $ (610,308) | $ (674,471) | $ 613,670 |
| Other comprehensive income: | |||
| Unrealized loss on securities available-for-sale, net of income tax provision of $0, $0, and $0, respectively | (1,401) | (211) | (186) |
| Foreign currency translation gain, net of income tax provision of $0, $0, and $0, respectively | 3,732 | 825 | 522 |
| Total other comprehensive income | 2,331 | 614 | 336 |
| Comprehensive (loss) income | (607,977) | (673,857) | 614,006 |
| Net product sales | |||
| Revenues: | |||
| Revenue | 1,706,516 | 1,385,566 | 1,000,598 |
| Royalty revenues | |||
| Revenues: | |||
| Revenue | 164,554 | 150,523 | 126,756 |
| Collaboration and license agreement revenues | |||
| Revenues: | |||
| Revenue | $ 91,342 | $ 38,282 | $ 1,048,182 |
SGEN Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 319,940 | $ 424,834 |
| Short-term investments | 1,415,130 | 1,735,202 |
| Accounts receivable, net | 501,912 | 389,256 |
| Inventories | 427,211 | 200,663 |
| Prepaid expenses and other current assets | 138,340 | 119,239 |
| Total current assets | 2,802,533 | 2,869,194 |
| Property and equipment, net | 248,179 | 210,073 |
| Operating lease right-of-use assets | 46,738 | 57,889 |
| Intangible assets, net | 237,516 | 260,593 |
| Goodwill | 274,671 | 274,671 |
| Other non-current assets | 64,895 | 47,184 |
| Total assets | 3,674,532 | 3,719,604 |
| Current liabilities: | ||
| Accounts payable | 207,851 | 114,824 |
| Accrued liabilities and other | 610,553 | 454,030 |
| Total current liabilities | 818,404 | 568,854 |
| Long-term liabilities: | ||
| Operating lease liabilities, long-term | 43,474 | 56,665 |
| Other long-term liabilities | 8,835 | 28,946 |
| Total long-term liabilities | 52,309 | 85,611 |
| Commitments and contingencies | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value, 5,000 shares authorized; none issued | 0 | 0 |
| Common stock, $0.001 par value, 250,000 shares authorized; 186,559 shares issued and outstanding at December 31, 2022 and 183,381 shares issued and outstanding at December 31, 2021 | 187 | 183 |
| Additional paid-in capital | 4,954,469 | 4,607,816 |
| Accumulated other comprehensive income | 3,510 | 1,179 |
| Accumulated deficit | (2,154,347) | (1,544,039) |
| Total stockholders' equity | 2,803,819 | 3,065,139 |
| Total liabilities and stockholders' equity | $ 3,674,532 | $ 3,719,604 |